NC-TOSHIBA
1.6.2022 15:07:09 CEST | Business Wire | Press release
Toshiba Global Commerce Solutions, market share leader in retail store technology, announced today that it has been named a Leader in the IDC MarketScape: “Worldwide Point-of-Sale Software Vendors in Grocery and Food Store Retail 2022 Vendor Assessment (doc #US46743220, May 2022).”
“We are honored to be recognized as a leader,” said Rance Poehler, president and CEO, Toshiba Global Commerce Solutions. “We are moving rapidly into a new world where retail touchpoints must be seamlessly interconnected to create the kind of personalized and cohesive shopping experience that consumers have come to expect—at POS and throughout the store. Today, we are working closely with retailers to accelerate this transformation by unifying channels and digitizing their stores with our ELERA commerce platform and solutions, enabling them to quickly adapt and scale to deliver an exceptional retail experience.”
IDC MarketScape is the IT industry’s premier vendor assessment tool providing in-depth quantitative and qualitative technology market assessment. This 2022 IDC MarketScape assesses the capabilities and strategies of enterprise POS software solution providers that have a significant presence in the global grocery/food store segment. A key component of the evaluation is how IT buyers perceive the benefits of POS software in meeting the unique and ever-changing needs of grocery stores as well as the providers’ strategy and commitment to innovation to enable retailers’ ongoing omni-channel success.
“Successful players need to enable the visibility and democratization of data that comes from each customer touchpoint,” noted Margot Juros, research manager, worldwide retail technology strategies, IDC in the assessment. “One key differentiator among leaders in this space is the ability to provide real-time, actionable data to help grocery retailers make impactful changes at the store level.”
The report highlights Toshiba’s key strengths:
Global presence : “Toshiba Global Commerce Solutions stands out with its global presence, large installed base of POS systems, strong omni-channel vision and road map, long record of innovation, and demonstrated ability to meet evolving business needs, making Toshiba a formidable competitor.”
Next-level unified commerce : “Toshiba's ELERA platform stands apart from many competitors with its embrace of modern technologies throughout the platform to take unified commerce to the next level including IoT, edge, data analytics/visualization, and computer vision. Its microservices architecture allows seamless interaction of applications of the retailer's choice across channels while maintaining a common user experience across the platform (head or headless).”
Flexibility : “Toshiba offers retailers great flexibility for payments from the platform, acting as a connector between POS and payment gateways. Retailers can use an existing payment gateway or Toshiba gateway thereby eliminating the need for third-party vendors in the middle.”
For more information, please register here .
About IDC MarketScape:
IDC MarketScape vendor assessment model is designed to provide an overview of the competitive fitness of ICT (information and communications technology) suppliers in a given market. The research methodology utilizes a rigorous scoring methodology based on both qualitative and quantitative criteria that results in a single graphical illustration of each vendor’s position within a given market. IDC MarketScape provides a clear framework in which the product and service offerings, capabilities and strategies, and current and future market success factors of IT and telecommunications vendors can be meaningfully compared. The framework also provides technology buyers with a 360-degree assessment of the strengths and weaknesses of current and prospective vendors.
About Toshiba Global Commerce Solutions
Toshiba Global Commerce Solutions is a global market share leader in retail store technology and retail’s first choice for unified commerce solutions. Together with a global team of dedicated business partners, we advance the future of retail with innovative commerce solutions that enhance customer engagement, transform the in-store experience, and accelerate digital transformation. To learn more, visit commerce.toshiba.com and engage with us on Twitter , LinkedIn , Facebook , Instagram and YouTube .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220601005295/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom